Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Expenses (2016 - 2017)

Northwest Biotherapeutics (NWBO) has 8 years of Accumulated Expenses data on record, last reported at $933000.0 in Q1 2017.

  • For Q1 2017, Accumulated Expenses fell 21.53% year-over-year to $933000.0; the TTM value through Mar 2017 reached $933000.0, down 21.53%, while the annual FY2016 figure was $901000.0, 31.17% down from the prior year.
  • Accumulated Expenses reached $933000.0 in Q1 2017 per NWBO's latest filing, up from $901000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.3 million in Q2 2016 and bottomed at $655000.0 in Q2 2014.
  • Average Accumulated Expenses over 5 years is $1.0 million, with a median of $1.1 million recorded in 2013.
  • Peak YoY movement for Accumulated Expenses: plummeted 85.71% in 2013, then soared 81.37% in 2015.
  • A 5-year view of Accumulated Expenses shows it stood at $842000.0 in 2013, then skyrocketed by 43.82% to $1.2 million in 2014, then grew by 8.09% to $1.3 million in 2015, then crashed by 31.17% to $901000.0 in 2016, then rose by 3.55% to $933000.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $933000.0 in Q1 2017, $901000.0 in Q4 2016, and $1.3 million in Q3 2016.